Brokerages expect that Portola Pharmaceuticals Inc (NASDAQ:PTLA) will report $2.42 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Portola Pharmaceuticals’ earnings, with the highest sales estimate coming in at $2.44 million and the lowest estimate coming in at $2.40 million. Portola Pharmaceuticals posted sales of $13.69 million during the same quarter last year, which suggests a negative year-over-year growth rate of 82.3%. The firm is expected to report its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Portola Pharmaceuticals will report full-year sales of $2.42 million for the current year, with estimates ranging from $15.14 million to $18.66 million. For the next financial year, analysts forecast that the company will report sales of $166.88 million per share, with estimates ranging from $134.61 million to $203.47 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Portola Pharmaceuticals.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.08. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The firm’s quarterly revenue was down 58.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.64) earnings per share.
Shares of Portola Pharmaceuticals (PTLA) traded up $0.35 during trading hours on Thursday, hitting $49.76. 63,953 shares of the stock traded hands, compared to its average volume of 1,409,400. The stock has a market cap of $3,220.00, a P/E ratio of -11.52 and a beta of 1.21. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a twelve month low of $22.71 and a twelve month high of $67.10.
In other news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in PTLA. Renaissance Technologies LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter valued at $21,187,000. Kornitzer Capital Management Inc. KS increased its holdings in shares of Portola Pharmaceuticals by 38.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock valued at $39,324,000 after acquiring an additional 202,925 shares during the period. Zevenbergen Capital Investments LLC increased its holdings in shares of Portola Pharmaceuticals by 71.4% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 452,190 shares of the biopharmaceutical company’s stock valued at $25,400,000 after acquiring an additional 188,320 shares during the period. Blue Jay Capital Management LLC acquired a new position in shares of Portola Pharmaceuticals in the 2nd quarter valued at $6,740,000. Finally, State Street Corp increased its holdings in shares of Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock valued at $117,164,000 after acquiring an additional 105,207 shares during the period. 87.25% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/04/portola-pharmaceuticals-inc-ptla-expected-to-announce-quarterly-sales-of-2-42-million.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.